



News Release

Lonza Makes More Possible with New Science-Based Formulations and Extended Clean-Label Capabilities at Vitafoods

- **Lonza Consumer Health & Nutrition, Booth G10, Vitafoods Europe, Geneva (CH), 7-9 May 2019**

Basel (CH), 18 April 2019 – Lonza is highlighting its integrated health and nutrition solutions for different life stages at this year's Vitafoods Europe, where it will focus on supporting mobility across all ages. At booth G10, Lonza will present its latest ready-to-go innovation concepts featuring UC-II® undenatured type II collagen for joint health, in combination with other trending ingredients.

As the show's Official Capsule Sponsor, Lonza will also be unveiling new additions to its portfolio of unique clean-label dosage forms. Thanks to the introduction of the Capsugel® Vcaps® Plus Red Radish and Spicy Yellow capsules, an expanding spectrum of plant-based, food colored capsules will soon be available for supplement brands looking to create bright, visually distinctive products.

Moving with the Times™

With seven out of 10 European supplement users now seeking joint health products, Lonza's Moving with the Times™ platform centers around its UC-II® ingredient.¹ UC-II® undenatured type II collagen has been shown to have a unique mode of action that triggers the natural rebuilding of cartilage, therefore improving joint comfort, mobility and flexibility.

The small 40 mg required daily dose of the UC-II® ingredient can be delivered in a tiny Vcaps® Plus capsule, or combined with other ingredients that have complementary effects. At booth G10, Lonza will feature a series of combination products enabled by its advanced capsule and dosage form technologies, including UC-II® undenatured type II collagen with omega-3s or highly bioavailable curcumin for anti-inflammatory benefits. The UC-II® ingredient can also be formulated alongside vitamin K2 in a Licaps® liquid-filled hard capsule, providing an all-in-one bone and joint health solution.

Lonza will review these science-based innovations featuring UC-II® undenatured type II collagen during a seminar: *Moving with the Times™: A New Generation Joint Health*

Solution for Today's Consumer, which takes place at 14:20 CEST on Tuesday, 7 May, in the Life Stages Theater.

Clean-Label Gets Colorful

A pioneer in high performance capsules, Lonza continues to bring new innovations to the European market following the launch of the industry's first clean-label food colored capsules last year. Its vegetarian Vcaps® Plus capsules can now be tinted using colored foods to achieve a vibrant Red Radish or Spicy Yellow color.

Vitafoods Europe 2019 also marks the official launch of the Clean Label Alliance in Europe. As a founding member of the group in the United States, Lonza will be working to support manufacturers in meeting evolving consumer preferences for products that have no additives or preservatives, as well as a natural, vegetarian or vegan positioning.

Visit www.capsugel.com for more information, or to book an appointment with Lonza's expert team.

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Lonza Pharma Biotech & Nutrition segment and our Lonza Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion

¹ Natural Marketing Institute, 2015 Lonza SORD Report (unpublished).



in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.

Lonza Contact Details

Dirk Oehlers, Head Investor Relations

Lonza Group Ltd

Tel +41 61 316 8540

dirk.oehlers@lonza.com

Constance Ward, Head External Communications

Lonza Group Ltd

Tel +41 61 316 8840

constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.